Imperial College London

Professor Paul M. Matthews

Faculty of MedicineDepartment of Brain Sciences

Edmond and Lily Safra Chair, Head of Department



+44 (0)20 7594 2855p.matthews




Ms Siobhan Dillon +44 (0)20 7594 2855




E502Burlington DanesHammersmith Campus






BibTex format

author = {Matthews, PM and Rabiner, EA and Passchier, J and Gunn, RN},
doi = {10.1111/j.1365-2125.2011.04085.x},
journal = {Br J Clin Pharmacol},
pages = {175--186},
title = {Positron emission tomography molecular imaging for drug development},
url = {},
volume = {73},
year = {2012}

RIS format (EndNote, RefMan)

AB - Human in vivo molecular imaging with positron emission tomography (PET) enables a new kind of 'precision pharmacology', able to address questions central to drug development. Biodistribution studies with drug molecules carrying positron-emitting radioisotopes can test whether a new chemical entity reaches a target tissue compartment (such as the brain) in sufficient amounts to be pharmacologically active. Competition studies, using a radioligand that binds to the target of therapeutic interest with adequate specificity, enable direct assessment of the relationship between drug plasma concentration and target occupancy. Tailored radiotracers can be used to measure relative rates of biological processes, while radioligands specific for tissue markers expected to change with treatment can provide specific pharmacodynamic information. Integrated application of PET and magnetic resonance imaging (MRI) methods allows molecular interactions to be related directly to anatomical or physiological changes in a tissue. Applications of imaging in early drug development can suggest approaches to patient stratification for a personalized medicine able to deliver higher value from a drug after approval. Although imaging experimental medicine adds complexity to early drug development and costs per patient are high, appropriate use can increase returns on R and D investment by improving early decision making to reduce new drug attrition in later stages. We urge that the potential value of a translational molecular imaging strategy be considered routinely and at the earliest stages of new drug development.
AU - Matthews,PM
AU - Rabiner,EA
AU - Passchier,J
AU - Gunn,RN
DO - 10.1111/j.1365-2125.2011.04085.x
EP - 186
PY - 2012///
SN - 1365-2125
SP - 175
TI - Positron emission tomography molecular imaging for drug development
T2 - Br J Clin Pharmacol
UR -
UR -
VL - 73
ER -